

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs			
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS						
SWOG	S1312-ALL, CD22+, REL/REF, Inotuzumab+CVP	1	Y 1	CVP + Inotuzumab dose level 1	38	5	0	0	0	0	06/13/2014	3	3			
				2 CVP + Inotuzumab dose level 2	5	0	0	0	0	0						
				3 CVP + Inotuzumab dose level 3	11	0	0	0	0	0						
				4 CVP + Inotuzumab dose level 4	5	0	0	0	0	0						
				5 CVP + Inotuzumab dose level 5	11	0	0	0	0	0						
				6 CVP + Inotuzumab MTD	4	4	4	3	1	0						
				41	4	4	3	1	0							
S1318-ALL, Age 65+, Ph±, Blinatumomab	1	T	1	Induction: Ph-	44	31	3	0	0	0	06/30/2015	149	58			
				2 Induction: Ph+/Ph-like	16	0	0	0	0	0						
					47	3	0	0	0	0						
				2	Y	3	Post-remission: Ph-	44	20	2	0	0	0	06/30/2015		
							4 Post-remission: Ph+/Ph-like	12	0	0	0	0	0			
								32	2	0	0	0	0			
3	Y	5	Maintenance: Ph-	44	14	7	1	0	0	06/30/2015						
			6 Maintenance: Ph+/Ph-like	10	8	0	0	0	0							
				24	15	1	0	0	0							
S1612-AML/MDS, Age 60+, Aza/Novel Therapeutics	1	Y	0	FLT3 Testing	1670	77	77	75	55	20	02/02/2018	199	73			
					77	77	75	55	20	5						
				2	Y	1	Azacitidine	1670	18	18	17	9	4	02/02/2018		
							2 Azacitidine + Nivolumab	17	17	17	13	3	1			
3 Azacitidine + Midostaurin	17	17	16				14	3	1							
				52	52	50	36	10	2							
S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT	1	N	1	Induction/Consolidation	94	97	0	0	0	0	08/25/2010		11			
					97	0	0	0	0	0						
				2	Y	2	Vincristine/Pred/Dasatinib	22	0	0	0	0	08/25/2010			
								22	0	0	0	0	0			
3	Y	3	Allo stem cell transplant	37	43	0	0	0	0	08/25/2010						
				43	0	0	0	0	0							
4	Y	4	Dasatinib	42	0	0	0	0	08/25/2010							

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
					LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
				42	0	0	0	0	0			
Yes	E1910-BCR-ABL-neg, B ALL, Blinatumomab	1 E	Total Registrations	91	26	14	7	1	0	06/06/2014	1	83
				91	26	14	7	1	0			
	E2906-AML, Age 60+, Clo vs Dauno+Cy	1 E	Total Registrations	75	0	0	0	0	0	08/06/2012		71
				75	0	0	0	0	0			
No	E1910-BCR-ABL-neg, B ALL, Blinatumomab	0 E	Total Registrations	128	39	20	10	3	1	06/06/2014	1	83
				128	39	20	10	3	1			
		2 E	Total Registrations	57	15	11	4	1	0	06/06/2014		
				57	15	11	4	1	0			
		3 E	Total Registrations	45	11	7	4	2	0	06/06/2014		
				45	11	7	4	2	0			
		4 E	Total Registrations	21	7	4	3	1	0	06/06/2014		
				21	7	4	3	1	0			
	E2906-AML, Age 60+, Clo vs Dauno+Cy	0 E	Total Registrations	19	0	0	0	0	0	08/06/2012		71
				19	0	0	0	0	0			
		2 E	Total Registrations	21	0	0	0	0	0	08/06/2012		
				21	0	0	0	0	0			
		3 E	Total Registrations	11	0	0	0	0	0	08/06/2012		
				11	0	0	0	0	0			
	NHLBIMDS-LEUK, National MDS Study	1 E	Total Registrations	16	11	9	5	0	0	12/22/2016	248	104
				16	11	9	5	0	0			

20-AUG-2018 6:10
LEUK Open Studies with No Registrations

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1712 CML, chronic phase, TKI +/- Ruxolitinib	1 Randomization	20-Jul-18